A decrease of <i>MHCII</i>, <i>Dl4</i>, and <i>Ccl25</i> but an increase in <i>Il7</i> in the <i>Foxn1</i>^<i>lacZ</i> thymus. by Shiyun Xiao (75798)

Viability of <i>MRE11</i>, <i>mre11A470T</i>, <i>rap1-5</i>, <i>and mre11A470T rap1-5</i>. by In-Joon Baek (4423057)

“…<i>mre11A470T</i> and <i>mre11A470T rap1-5</i> cells had decreased viability only at 37°C. …”

Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography by O. Stivalet (6890189)

“…The receiver-operating-characteristic curve was used to define a cut-off point corresponding to the best area under the curve (AUC; [CI95%]) to detect arterial stenosis ≥50% as determined by the CTA.…”

A null mutation in <i>apt</i> suppresses the Cu(II) sensitivity of the <i>cop</i>^- strain. by Javiera Norambuena (137228)

Administration of anti-CD25 antibody decreases the early and late organ fungal burdens of resistant and susceptible mice. by Maíra Felonato (296591)

The effect of STOX1A on cell proliferation in the neuroblastoma cell-line SH-SY5Y. by Daan van Abel (214754)

“…(C) Overexpression and knockdown of STOX1A was determined with quantitative RT-PCR showing a mean 21 fold (mean ΔΔCt 4.4) increase in mRNA expression for STOX1A in stably transfected SH-SH5Y cells compared to the controls (Left bar) and a mean 71 fold (mean ΔΔCt 6.15) decreased mRNA expression for STOX1A siRNA transfected SH-SY5Y cells compared to the scrambled controls (right bar). …”

Change of the switch point between dual-E and single-E control with decreasing values of <i>k</i>₉, <i>k</i>₁₁, and <i>k</i>₁₃. by Qaiser Waheed (5095328)

The I827K substitution destabilizes the 3D fold of E6AP^C-lobe (residues 761–875). by Steven A. Beasley (9099461)

“…<p>(A) The assigned ¹H-¹⁵N-HSQC spectrum of 3.5 mM human E6AP catalytic C-lobe (residues 761–875) using the one-letter amino acid code and residue number according to the human E6AP sequence. …”

Results of comparison between Model5 and Model9. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Results of comparison between Model5 and Model10. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Klf5 activates the transcription of the eIF5a gene through direct binding to its promoter. by Dong Ma (584680)

Subjects:

Phlorizin decreased renal GTTR uptake, and increased serum drug levels <i>in vivo</i>. by Meiyan Jiang (438439)

Procedures of sampling and measurements. by Xuegang Mao (599968)

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Data extraction grid. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

“…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)